Answers are grounded in this paper and cite their sources.
Although several anti-multiple myeloma (MM) drugs have been developed to improve the prognosis of its patients, MM is still an incurable disease. At present, the development of new therapeutic agents that are highly specific to MM cells and have action mechanisms different from those of the existing drugs is highly required. As important candidates, molecules that target AMP deaminase 1 (AMPD1), which is specifically expressed in plasma cells and MM cells, might be novel agents for MM therapy. Here, we report the design, synthesis, and evaluation of new AMPD1 inhibitors based on reported AMPD1 inhibitors. These results, including their structure–activity relationships, should provide useful information for further development of therapeutic agents for MM patients.
No takes yet. Share an insight, caveat, or question.
Kobayakawa et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: